IOP substantially reduced through 5 years in patients with OAG after iStent inject implantation
Implantation with a second-generation trabecular micro-bypass stents (iStent inject) substantially reduced IOP in patients with open-angle glaucoma (OAG) through 5 years, according to a presentation at the 38th Congress of the European Society of Cataract and Refractive Surgeons.
In this 5-year prospective study, 57 patients (57 eyes) with OAG being treated with 1 preoperative medication, underwent implantation. Efficacy outcomes included ≥ 20% IOP reduction versus baseline and IOP ≤ 18 mmHg.
In more than 80% of eyes, IOP endpoints were achieved at 5 years with no medication.
Mean IOP decreased by 47% to 12.9 mmHg compared to pre-op washout IOP 24.4 ± 1.3 at 5 years. More than 90% of eyes remained medication-free throughout follow-up.
No intraoperative or device-related adverse events were recorded.
Aptel F, et al. Sustained 5-year safety and IOP outcomes in open-angle glaucoma subjects treated with trabecular micro-bypass stents. Presented at: 38th Congress of the European Society of Cataract and Refractive Surgeons, October 2-4, 2020.